Tissot Claire, Gay Pierre, Brun Clément, Froudarakis Marios E
Department of Pneumonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.
Clin Respir J. 2019 Mar;13(3):131-138. doi: 10.1111/crj.13005.
Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non-small-cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.
肺癌是全球最常见的致命性恶性肿瘤。大约75%的非小细胞肺癌（NSCLC）患者在晚期或转移阶段被诊断出来。自2007年以来，伴有恶性胸腔积液（MPE）的NSCLC患者被分期为M1期疾病。在过去几十年中，化疗药物未能显著提高转移性疾病患者的生存率。本综述旨在总结肺癌合并MPE患者近期所开发疗法的实际情况。
